bioMérieux : advancing diagnostics to improve public health

Global player in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries trough 38 subsidiaries and a large network of distributors. In 2007, the turnover of bioMerieux amounted to 1063 billion euros, of which 84% was achieved abroad.

bioMerieux provides diagnostic solutions (reagents, instruments and software) that determine the cause of a disease or contamination to improve the health of patients and ensure consumer safety. Our products are used in the diagnosis of infectious diseases and bring the results to high medical value for emergency cardiovascular screening and monitoring of cancer. They are also used for the detection of micro-organisms in food products, pharmaceuticals and cosmetics. BioMerieux is a company listed on Euronext Paris